David A. Siegel Regeneron Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 938,500 shares of REGN stock, worth $522 Million. This represents 1.07% of its overall portfolio holdings.

Number of Shares

938,500

Previous 553,800 69.47%

Holding current value

$522 Million

Previous $351 Million 40.28%

% of portfolio

1.07%

Previous 0.82%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$483.07 - $625.6 $186 Million - $241 Million	384,700 Added 69.47%	938,500 $493 Million
Q1 2025 May 15, 2025	BUY	$634.14 - $744.83 $351 Million - $412 Million	553,800 New	553,800 $351 Million
Q3 2024 Nov 14, 2024	SELL	$1024.09 - $1201.76 $102,408 - $120,176	-100 Reduced 10.0%	900 $946,000
Q2 2024 Aug 14, 2024	BUY	$883.2 - $1071.19 $883,200 - $1.07 Million	1,000 New	1,000 $1.05 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $178 Million - $203 Million	-230,000 Reduced 94.69%	12,900 $11.3 Million
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $39.1 Million - $47.6 Million	-56,400 Reduced 18.84%	242,900 $200 Million
Q2 2023 Aug 14, 2023	BUY	$700.03 - $830.35 $62.7 Million - $74.3 Million	89,500 Added 42.66%	299,300 $215 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $110 Million - $133 Million	161,300 Added 332.58%	209,800 $172 Million
Q4 2022 Feb 14, 2023	SELL	$705.89 - $766.39 $47.6 Million - $51.7 Million	-67,400 Reduced 58.15%	48,500 $35 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $93.6 Million - $118 Million	-163,100 Reduced 58.46%	115,900 $79.8 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $93.6 Million - $118 Million	-163,100 Reduced 58.46%	115,900 $79.8 Million
Q2 2022 Aug 15, 2022	SELL	$548.35 - $738.84 $115 Million - $155 Million	-210,200 Reduced 42.97%	279,000 $165 Million
Q1 2022 May 16, 2022	BUY	$595.12 - $698.43 $59.9 Million - $70.3 Million	100,700 Added 25.92%	489,200 $342 Million
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $211 Million - $261 Million	388,500 New	388,500 $245 Million
Q4 2020 Feb 16, 2021	SELL	$478.3 - $607.98 $25.3 Million - $32.1 Million	-52,799 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$544.75 - $658.21 $37.6 Million - $45.5 Million	-69,100 Reduced 56.69%	52,799 $29.6 Million
Q2 2020 Aug 14, 2020	BUY	$493.32 - $643.92 $35.7 Million - $46.6 Million	72,299 Added 145.76%	121,899 $76 Million
Q1 2020 May 15, 2020	BUY	$336.18 - $494.43 $3.53 Million - $5.19 Million	10,498 Added 26.85%	49,600 $24.2 Million
Q4 2019 Feb 14, 2020	SELL	$274.13 - $376.51 $66.9 Million - $91.9 Million	-244,199 Reduced 86.2%	39,102 $14.7 Million
Q3 2019 Nov 14, 2019	BUY	$273.46 - $318.39 $11.6 Million - $13.5 Million	42,300 Added 17.55%	283,301 $78.6 Million
Q2 2019 Aug 14, 2019	SELL	$299.6 - $414.82 $15.2 Million - $21 Million	-50,600 Reduced 17.35%	241,001 $75.4 Million
Q1 2019 May 15, 2019	SELL	$372.08 - $439.57 $104 Million - $123 Million	-279,400 Reduced 48.93%	291,601 $120 Million
Q4 2018 Feb 14, 2019	SELL	$335.82 - $403.04 $15.4 Million - $18.5 Million	-45,800 Reduced 7.43%	571,001 $213 Million
Q3 2018 Nov 14, 2018	SELL	$351.14 - $408.51 $42.9 Million - $50 Million	-122,300 Reduced 16.55%	616,801 $249 Million
Q2 2018 Aug 14, 2018	BUY	$284.6 - $344.99 $11 Million - $13.4 Million	38,800 Added 5.54%	739,101 $255 Million
Q1 2018 May 15, 2018	BUY	$315.82 - $393.78 $101 Million - $126 Million	319,263 Added 83.79%	700,301 $241 Million
Q4 2017 Feb 14, 2018	BUY	$358.63 - $469.95 $137 Million - $179 Million	381,038	381,038 $143 Million

Others Institutions Holding REGN

# of Institutions

1,411

Shares Held

88.7M

Call Options Held

1.96M

Put Options Held

1.7M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $59.7B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account